If those predictions are correct, AZ’s oral PCSK9 could have to contend with cut-price antibody drugs, a long-acting siRNA benefiting from marketing alongside Novartis’ blockbuster heart ...

Unlike inclisiran’s siRNA mechanism, VERVE-101 uses an mRNA-encoded adenine base editor plus a guide RNA that specifically targets the PCSK9 gene. Base editing alters a single base pair in the ...

Objective To evaluate the potential effects of proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9-mAb) on high-sensitivity C reactive protein (hs-CRP) concentrations. Design A ...

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

PCSK9, which mediates post-translational destruction of LDL receptors, is raised in HoFH and is further raised by statins. LDL-C, following apheresis, quickly rebounds due to increased synthesis ...

ART101 注射液，作为昂拓生物自主研发的 siRNA 药物，通过靶向抑制肝脏 AGT mRNA 的表达，减少 AGT 蛋白生成，进而实现降压效果。 鼎泰集团助力 ART101注射液 等寡核苷酸药物的非临床研究 鼎泰团队凭借领先的专业技术、丰富的项目经验及优质资源，为 ART101 注射液 ...

研发进展是降脂药行业的核心亮点。PCSK9 作为成熟靶点，竞争激烈，现有单抗和 siRNA 两种机制药物上市，且新技术路线不断涌现，如反义核苷酸 ASO、靶向环肽疗法、疫苗和基因编辑技术等，为降脂治疗带来新希望。Lp(a)作为降脂新靶点备受关注，全球多家药企 ...